JS Bin

Board of Directors

served as Deputy Director of the Stanford Linear Accelerator Center's Computation Group and later as Visiting Associate Professor of Computer Science at the State University of New York at Buffalo. From 1973 to 1978, he worked for IBM, at the IBM Scientific Center in Haifa, Israel and the IBM General Products Division in San Jose. In 2002, Dr. Harry J. Saal was chosen by the US Department of Justice to lead the Technical Committee charged with monitoring and enforcing the Microsoft Antitrust case. He served as Chairman of the Committee through the May 2011 expiration of the Judgment.Dr. Saal was the founder and CEO of Network General Corporation, the first company wholly dedicated to the area of network diagnostics and the creator of the eponymous "Sniffer" network analyzer. From 1993 through 1995, Dr. Saal served as founding CEO and President of Smart Valley, Inc., a non-profit organization chartered to create a regional electronic community based on an advanced information infrastructure and the collective ability to use it.

He has served as Director of several private and publicly traded high technology firms. Ernst & Young named Dr. Saal the Bay Area 1990 Software Entrepreneur of the Year and he is also the recipient of the ADL Torch of Liberty Award, the ACM/Computer Museum 1994 Computer Bowl MVP, and the JNF Tree of Life Award. He is active in philanthropy and community affairs, serving as Chair of the Arthritis Foundation Northern California Chapter for 2010 and 2011, among others. From 1998 through 2003 he served as President of Cultural Initiatives Silicon Valley, a non-profit organization which links a network of public and private cultural agencies and organizations to enhance arts and culture in Silicon Valley. He is currently the Chair of ZERO1, an organization that is enhancing the intersection of art and technology in Silicon Valley and internationally. He has served as Chairman of the Board of the Community Foundation Silicon Valley (from whom he received the 1996 Corporate Community Involvement Award) and Vice Chairman of the American Leadership Forum, Silicon Valley Chapter; in 1995 received their John W. Gardner Leadership Award. As well, he currently serves on the boards of the American Institute of Mathematics, the San Jose Airport Arts Oversight Commission and Numenta, Inc. In 1997, Columbia University awarded Dr. Saal its highest honor, the John Jay Award. He received his B.A. (Magna Cum Laude) from Columbia University in 1963, and his Ph.D. in High Energy Physics, Columbia University, in 1969.

is a member of the US National Academy of Sciences (1988) and is currently on leave from Boston University (Professor of Biomedical Engineering and Director of the Center for Advanced Biotechnology). Founder and CSO (since 1998) of Sequenom, Inc. His main areas of expertise: biophysics, molecular genetics, molecular biology, genomics, bioinformatics. His scientific interests include mass-spectrometry, prenatal diagnostics, in vivo RNA detection and epigenetics. He made important contributions to understanding of DNA-protein interactions and pioneered physical mapping of whole chromosomes. Invented (1984) and developed pulse field gel electrophoresis for analysis of very large DNA molecules. He is also founder of SelectX Pharmaceuticals and DiThera. His copious awards include Eli Lilly Award in Biological Chemistry (1978), Biochemical Analysis Prize of the German Society of Clinical Chemistry (1988), ISCO Award for Advances in Biochemical Instrumentation (1989), H.A. Sober Award (American Society for Biochemistry and Molecular Biology, 1990), and E.M. Gray Award (Biophysical Society, 2000). (Co)authored several books (including the 3-volume textbook, Biophysical Chemistry) and more than 450 per-reviewed papers, as well as more than 60 patents. He received his BA from Columbia University in 1963 and a Ph.D. from the University of California, Berkeley in 1966.

specializes in biotechnology reagents, genomics, proteomics, and biopharmaceutical research companies. He was the founding CEO of Coda Genomics, a synthetic biology and biofuels company. Dr. Molinari is on the biotech screening committee of the Life Science Angels. He served as a genomics affiliate to the Institute for the Future, a Menlo Park-based think tank. He was the co-founding CEO and president of Protogene Laboratories, Inc., and from 1994 to 1996 led that company to become the world's largest supplier of custom DNA before it was acquired by Life Technologies, Inc. (now Invitrogen). He then ran a spin-off of Protogene for several years which developed ink jet technology for custom DNA chips. Prior to Protogene, Dr. Molinari served as a strategic advisor in the startup of Nanogen, Affymetrix, and Sequenom. Earlier, Dr. Molinari served as the founding CEO of Avitech Diagnostics, a company with DNA sequencing and mutation detection technology (which became part of Variagenics, Inc.) and was a consultant specializing in biotechnology at McKinsey & Co. Dr. Molinari has an A.B. and an MBA from Dartmouth College and a Ph.D. in biophysical chemistry from Brown University

did postdoctoral research in the Department of Biochemistry, University of Oxford, UK, from 1995 to 2000, focusing on the overlap of bioorganic, combinatorial and surface chemistries. From 2000 to 2002 (San Diego, USA), and from 2002 to 2006 (UK) he worked in the biotech industry developing chemical tools for genomics and proteomics. At Retrotope, Dr. Shchepinov has focused on the use of stable isotopes as a fortification of essential nutrients to protect against diseases of aging and age-related oxidative stress. Dr. Shchepinov received his MS in chemistry and biotechnology from the Mendeleev Institute of Chemical Technology, Moscow, USSR, and a PhD in bioorganic chemistry from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, in 1994.

has served as the President and CEO of the National Research Center for Environment and Health, GSF-National Research Center for Environment and Health GmbH, a governmental research center in Munich, Germany from 1995 to 2006. He has over 20 years of experience in key senior executive roles. From 1984 to 1995, he worked as the Head of the Pharmaceuticals Division and Head of Worldwide Pharmaceutical Research at The Hoechst Group. He was also the Head of the International Pharmaceuticals Division of the Hoechst AG Group and Head of worldwide Pharma Research of Hoechst AG from 1989 to 1991. Dr. Afting has been a member of the medical faculty at the University of Goettingen since 1985. Dr. Afting was a member of the Advisory Committee on Science and Technology to German Chancellor Helmut Kohl from 1996 to 1997 and from 1996 to 2005 was a member of the German National Advisory Committee on Health Research to the State Secretaries of Science, Technology and Health. Dr. Afting holds a Ph.D. Degree in Chemistry and an M.D. degree from the University of Freiburg, Breisgau.

is a Russian businessman and philanthropist, and co-founded Euroset, Russia’s leading mobile phone retailer. After selling his stake in Euroset in 2008, Mr. Artemev has invested a significant part of the proceeds in several international research projects aiming at slowing down ageing. He continues to sponsor research into ageing by New York University and supports biological laboratories in Russia, Ukraine, China and Germany. Mr. Artemev is major donor and trustee of the UK charity Biogerontology Research Foundation.

is chairman of Armetheon, a California company conducting a Phase 3 trial of its novel oral anticoagulant. From 2011 till 2015 as CEO of Heart Metabolics he raised capital for and organized the late stage development of an orphan treatment for a rare genetic heart disease, hypertrophic cardiomyopathy (HCM). In 2007 Peter cofounded Optivia Biotechnology a leading transporter biology company. In 1997 Peter co-founded ARYx Therapeutics (NASDAQ:ARYX) where as CEO then as president from 2005 to 2010 he co-invented and developed 4 novel drugs. In 1990 he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996 he in-licensed and invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009. Prior to 1992, Peter was as an assistant professor of medicine at Washington University in St. Louis where his research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates the epithelial mesenchymal transition (EMT). He received his medical degree from University of Liverpool in 1980 and undertook post-graduate training at Johns Hopkins Hospital and The University of Virginia.

He is a board certified cardiologist, a Fellow of the American College of Cardiology (FACC), co-inventor on 50 patents and author of 29 original scientific articles in Science, Biochemistry, Circulation, Cancer, JCI, and JBC. He serves as adjunct clinical faculty at Stanford University and as a board member of the California Healthcare Institute (CHI) where he was responsible for championing various pieces of legislation in particular, the 2011 Leahy-Smith Patent Reform Act and the 2012 GAIN (Generate Antibiotic Incentives Now) Act.

is Managing Director for VDP, LLC, an independent consulting agency focused on guiding Research and Development for the Biotechnology and Pharmaceutical Industries and private investors. At VDP, LLC, Dr. Van der Ploeg focuses on supporting R&D initiatives from a strategic and tactical perspective, as an integrated member of Management and R&D teams. Dr. Van der Ploeg is CSO for Rhythm pharmaceuticals and functions as Senior Advisor for Strategy and Planning at Somalogic, Inc., he is a member of the board of Directors for Neurotez, Inc., and Retrotope Inc., and he functions as an advisor to DeuteRx, LLC. and is a member of the SAB for Excellentia Global partners.

Dr. Van der Ploeg’s expertise includes development of Diagnostics and Therapeutics including Cancer, Neurodegenerative disorders, Metabolic disorders and Infectious diseases. Prior to starting VDP, LLC Dr. Van der Ploeg was the Sr. Vice President of Integrative Medicine and Translational Science at Abraxis/Celgene. Previously, Dr. Van der Ploeg held the position of, Vice president, Basic Research, and site head at Merck Research Laboratories Boston focused on oncology and neurodegenerative disease. Prior to starting Merck Research Laboratories Boston in December 2003, Dr. Van der Ploeg held diverse functions at Merck Research Laboratories including site head MRL San Diego and Head Obesity research for Merck Rahway and Banyu, Japan. At Merck, Dr. Van der Ploeg held leadership roles in obesity and metabolism, oncology, neurodegenerative disease research and diagnostics.

Following receipt of his Ph.D. Dr Van der Ploeg joined the faculty of the Dept of Genetics and Development of Columbia University, as an assistant Professor and received tenure at Columbia University in 1987. Dr Van der Ploeg held an adjunct faculty position at the Dept of Genetics and Development of Columbia University from 1992 through 2009. Dr. Van der Ploeg received numerous awards and grants for his research and has broadly published on his research in peer reviewed journals. He is an inventor on over 50 patents and patent applications. Dr. Van der Ploeg received his M.S. degree (Summa Cum Laude) in Biochemistry in 1980 from the University of Amsterdam and his Ph.D. in Biochemistry/Enzymology/Genetics in 1984 from the University of Amsterdam/Netherlands Cancer Research Center.